At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 18, 2026 at 16:30 ET
Wave Life Sciences reported strong updated Phase 1b/2a data for WVE-006 in AATD, showing restoration of wild-type M-AAT to protective levels (64.4% of total, matching low-risk MZ phenotype), reduction of toxic Z-AAT by up to 70.5%, and restored dynamic AAT production during acute phase responses. The drug was well-tolerated with monthly subcutaneous dosing, supporting a potential best-in-class profile. The company expects FDA feedback on an accelerated approval pathway mid-2026.
- WVE-006 restored wild-type M-AAT to 64.4% of total AAT, matching heterozygous MZ individuals with low disease risk.
- Treatment reduced harmful Z-AAT by up to 70.5% (200 mg biweekly multiple doses).
- Total AAT reached 11.9 µM (200 mg biweekly) and 13.6 µM (400 mg monthly).
- Dynamic AAT production was restored, with three instances of acute phase response-driven AAT elevation.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access